

Disclosures under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sno.	Requirement	Weblink
1.	Details of its business	https://balaxipharma.in/corporate-overview
2.	Terms and conditions of appointment of independent directors	https://balaxipharma.in/assets/images/corporatepolicies/TermsandConditionsforIDAppointment.pdf
3.	Composition of various committees of board of directors	https://balaxipharma.in/board-committees
4.	Code of conduct of board of directors and senior management personnel	https://balaxipharma.in/assets/images/corporatepolicies/Code_of_Conduct_for_Board_members_and_the_Senior_Management.pdf
5.	Details of establishment of vigil mechanism/ Whistle Blower policy	https://balaxipharma.in/assets/images/corporatepolicies/BPL_WHISTLE_BLOWER_POLICY.pdf
6.	Criteria of making payments to non-executive directors, if the same has not been disclosed in annual report	<p>Criteria of making payments to non-executive directors is disclosed on Page No. 66 of the Annual Report FY 2022-23 (https://balaxipharma.in/assets/images/articles/Balaxi_Pharmaceuticals_AR_2023.pdf)</p> <p>Further, the aforesaid criteria is also provided in the remuneration policy of the Company and can be accessed at: https://balaxipharma.in/assets/images/corporatepolicies/Remuneration_Policy.pdf</p>
7.	Policy on dealing with related party transactions	https://balaxipharma.in/assets/images/corporatepolicies/02-POLICY_ON_RELATED_PARTY_TRANSACTIONS.pdf
8.	Policy for determining 'material' subsidiaries	https://balaxipharma.in/assets/images/corporatepolicies/03-POLICY_ON_MATERIAL_SUBSIDIARY.pdf

Disclosures under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sno.	Requirement	Weblink
9.	<p>Details of familiarization programmes imparted to independent directors including the following details:-</p> <p>(i) number of programmes attended by independent directors (during the year and on a cumulative basis till date),</p> <p>(ii) number of hours spent by independent directors in such programmes (during the year and on cumulative basis till date), and</p> <p>(iii) other relevant details</p>	<p>https://balaxipharma.in/assets/images/corporatepolicies/FAMILIARIZATION_PROGRAMME_TO_INDEPENDENT_DIRECTORS_.pdf</p>
10.	<p>The email address for grievance redressal and other relevant details</p>	<p>https://balaxipharma.in/investor-contacts</p>
11.	<p>Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances</p>	<p>https://balaxipharma.in/investor-contacts</p>
12.	<p>Financial information including:</p> <p>(i) notice of meeting of the board of directors where financial results shall be discussed;</p>	<p>https://balaxipharma.in/board-meetings-notices</p>
	<p>(ii) financial results, on conclusion of the meeting of the board of directors where the financial results were approved;</p>	<p>https://balaxipharma.in/financial-results</p>
	<p>(iii) complete copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report etc;</p>	<p>https://balaxipharma.in/investor-annual-report</p>

Disclosures under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sno.	Requirement	Weblink
13.	Shareholding pattern	https://balaxipharma.in/investor-shareholder-pattern
14.	Details of agreements entered into with the media companies and/or their associates, etc	The company has not entered into any agreements with the media companies and/or their associates, etc.
15.	Schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet)] and presentations made by the listed entity to analysts or institutional investors.	https://balaxipharma.in/corporate-announcements
16.	<p>Audio or video recordings and transcripts of post earnings/quarterly calls, by whatever name called, conducted physically or through digital means, simultaneously with submission to the recognized stock exchange(s), in the following manner:</p> <p>(i) the presentation and the audio/video recordings shall be promptly made available on the website and in any case, before the next trading day or within twenty-four hours from the conclusion of such calls, whichever is earlier</p>	https://balaxipharma.in/corporate-announcements

Disclosures under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

	Requirement	Weblink
	<p>(ii) the transcripts of such calls shall be made available on the website within five working days of the conclusion of such calls: Provided that:</p> <p>a. The information under sub-clause (i) shall be hosted on the website of the listed entity for a minimum period of five years and thereafter as per the archival policy of the listed entity, as disclosed on its website.</p> <p>b. The information under sub-clause (ii) shall be hosted on the website of the listed entity and preserved in accordance with clause (a) of regulation 9.</p>	https://balaxipharma.in/corporate-announcements
17.	New name and the old name of the listed entity for a continuous period of one year, from the date of the last name change	Not Applicable
18.	Items in sub-regulation (1) of regulation 47	https://balaxipharma.in/press-releases
19.	With effect from October 1, 2018, all credit ratings obtained by the entity for all its outstanding instruments, updated immediately as and when there is any revision in any of the ratings.	https://balaxipharma.in/credit-rating

Disclosures under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sno.	Requirement	Weblink
20.	<p>Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year, uploaded at least 21 days prior to the date of the annual general meeting which has been called to inter alia consider accounts of that financial year</p> <p>Provided that a listed entity, which has a subsidiary incorporated outside India—</p> <p>(a) where such subsidiary is statutorily required to prepare consolidated financial statement under any law of the country of its incorporation, the requirement of this proviso shall be met if consolidated financial statement of such subsidiary is placed on the website of the listed entity.</p> <p>(b) where such subsidiary is not required to get its financial statement audited under any law of the country of its incorporation and which does not get such financial statement audited, the holding Indian listed entity may place such unaudited financial statement on its website and where such financial statement is in a language other than English, a translated copy of the financial statement in English shall also be placed on the website.</p>	<p>https://balaxipharma.in/subsidiaries-financial-statements</p>
21.	<p>Secretarial compliance report as per sub-regulation (2) of regulation 24A of these regulations.</p>	<p>https://balaxipharma.in/corporate-announcements</p>
22.	<p>Disclosure of the policy for determination of materiality of events or information required under clause (ii), sub-regulation (4) of regulation 30 of these regulations.</p>	<p>https://balaxipharma.in/assets/images/corporatepolicies/POLICY_FOR_DETERMINING_MATERIAL_INFORMATION.pdf</p>

Disclosures under Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sno.	Requirement	Weblink
23.	Disclosure of contact details of key managerial personnel who are authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s) as required under sub-regulation (5) of regulation 30 of these regulations.	https://balaxipharma.in/assets/images/corporatepolicies/Contact_Details_of_Key_Management_Personnel_who_are_authorized_for_the_purpose_of_determining_materiality_of_an_event_or_information.pdf
24.	Disclosures under sub-regulation (8) of regulation 30 of these regulations.	https://balaxipharma.in/corporate-announcements
25.	statements of deviation(s) or variation(s) as specified in regulation 32 of these regulations.	https://balaxipharma.in/corporate-announcements
26.	dividend distribution policy by listed entities based on market capitalization as specified in sub-regulation (1) of regulation 43A.	https://balaxipharma.in/assets/images/corporatepolicies/Dividend_Distribution_Policy.pdf
27.	annual return as provided under section 92 of the Companies Act, 2013 and the rules made thereunder	https://balaxipharma.in/assets/images/articles/Form_MGT_7_Final.pdf